“This article expresses my personal analysis based on publicly available financial data and market reports.”

When you think of eyewear, you might picture prescription glasses or trendy sunglasses. But now imagine that an everyday accessory is becoming the gateway to one of India’s most-talked-about IPOs of 2025. The company behind that vision? Lenskart Solutions. And the talk of the town? The so-called “GMP” or grey market premium. Suppose you’re wondering whether the Lenskart IPO GMP is worth your attention — and whether the early numbers make sense — read on. Because the story isn’t just about glasses, it’s about investor sentiment, hype, and where value might really lie.

What the “Lenskart IPO GMP” is telling us

The concept of GMP (grey market premium) – a non-official indicator of how much higher unlisted shares are trading over the issue price – often gives a hint of listing day sentiment. In Lenskart’s case:

• Before public subscription opened, GMP estimates ranged from 12 % to 18 %.
• One portal showed unlisted shares trading at ₹472, implying a 17.4 % premium over the upper issue band of ₹402. 
• On Day 1 of subscription, the public portion was subscribed to around 8-9% so far (early hours) despite the hype. 

What does this mean? The GMP suggests there is optimism among some investors about a listing gain. Yet the relatively modest subscription rate (at least so far) signals caution. It hints at a split: enthusiasm on one hand, but also recognition of risk (valuation, future profits) on the other.

Also Read

Trent Shares Fall 8% After Q3 Update Disappoints Investors

Why the market is excited about the Lenskart story

There are clear reasons for the buzz:

• Lenskart has positioned itself as a tech-enabled, omni-channel eyewear retailer in India and overseas.
• The company is tapping into a large under-penetrated eyewear and vision-care market in India — a theme many investors like.
• Big-ticket anchor investors and global funds backing the IPO add prestige and implied confidence. 

So yes — on the surface, Lenskart ticks many boxes of a trendy “consumer tech + retail brand India” story in 2025.

The flip side — “Lenskart IPO GMP” doesn’t yet guarantee smooth sailing

While the premium and business story are positive, there are important cautions:

• The valuation is stretched: According to the Moneycontrol at the upper band, the implied P/E multiple is very high (a number mentioned was 230x) based on FY25. 
• Despite profitability in the latest year, sustaining growth, margin expansion and global expansion are big challenges. 
• GMP is an unofficial, non-regulated indicator. It must be taken with a grain of salt (and indeed many articles remind investors of that). 

In short: the hype is real, the story is strong — but risk factors are equally real.

Also Read

Citibank Cuts Base Lending Rate to 7.00% – What It Means

My take — should you apply based on the “Lenskart IPO GMP”?

Here’s where I bring in a bit of my opinion:
If I were in your shoes, I’d consider the following:

If you’re a long-term investor who believes in Lenskart’s vision (eyewear + tech + India + global expansion), then applying at the lower end of the price band could make sense. The GMP suggests potential listing upside, and the business appears to have momentum.

If you’re a short-term investor hoping for a quick listing gain, tread very carefully. The GMP is encouraging, but the subscription rate, valuation, and execution risks suggest the upside might not be as large or as safe as it appears.
Personally, I lean cautiously positive: yes, I like the story — but I wouldn’t bet the house on huge gains. I’d apply, but only if the price feels reasonable and I’m prepared for the possibility of modest listing returns or waiting for real growth to kick in.

Conclusion

The “Lenskart IPO GMP” is flashing green lights for excitement — but not all signals are fully clear yet. If you believe in the company’s long game, this could be a smart entry. But if you’re chasing quick returns, the risk-reward leans toward caution. In my view: apply with optimism, but keep expectations tempered. The true test will come after listing — when the story meets execution.

Also Read Cipla Q2 Results

Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not US News Weeks. We advise investors to check with certified experts before making any investment decisions.

Source : The Economic Times & Moneycontrol - Lenskart IP0 Subscribed 4% Day 1